Merck discontinues development of 2 experimental cancer drugs after trial failures
Adds shares in paragraph 5, details and background throughout
Dec 16 (Reuters) -Merck MRK.N said on Monday it has discontinued the development of two experimental cancer drugs after their failure in several trials.
The pharmaceutical giant's decision comes after several setbacks for the drugs, vibostolimab and favezelimab, which were being tested separately in combination with its top-selling drug Keytruda for various forms of cancer.
On Monday, the company said it was stopping two trials of vibostolimab with Keytruda to treat non-small cell lung cancer after an analysis showed it was unlikely to succeed, while it also decided to cease development of favezelimab after reviewing its data.
"Following a careful analysis of the data, the decision has been made to discontinue development of these candidates to prioritize other ongoing programs," said Marjorie Green, head of oncology, global clinical development at Merck's research unit.
Shares of Merck were up nearly 1% in extended trading.
Vibostolimab belonged to a promising new class of immunotherapies called anti-TIGIT. This type of drug works by selectively binding itself to TIGIT, a receptor on immune cells, to activate the immune system against cancer cells and prevent a misguided immune attack against healthy cells.
Favezelimab was designed to prevent a protein called LAG-3 from binding to certain molecules on tumor cells. This activates the body's immune response and can reduce tumor growth.
Merck said it is informing study investigators for these trials and advised patients to contact their study team and physicians regarding the next steps and treatment options.
Reporting by Leroy Leo in Bengaluru; Editing by Alan Barona
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
